Affimed’s AFM13 Data Show Potential Of NK Cell Approach

Interim data from an investigator-sponsored Phase I/II study of Affimed N.V.’s bispecific engager AFM13 combined with natural killer (NK) cells in CD30-positive lymphomas bring the company a step closer toward carving out a registration path for the product. The latest data build on prior results of the therapy in peripheral T-cell lymphoma and also in combination with Merck & Co., Inc.’s PD-1 inhibitor Keytruda (pembrolizumab), but the new findings highlight the added benefit of the NK cell approach.

Affimed announced interim data on 22 November from 16 patients in the AFM13-104 trial who have CD30-positive relapsed or refractory Hodgkin’s lymphoma (HL) and two with non-Hodgkin’s lymphomas (NHL), including 12 patients – 11 with HL – who received the highest dose of 1x10^8 cells per kilogram, which is also the recommended Phase II dose